08-12-2025 19:49 via medpagetoday.com

Drug Combo Shows Benefits in Fit Patients With Acute Myeloid Leukemia

(MedPage Today) -- ORLANDO--Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit adults with acute myeloid leukemia (AML) compared with conventional induction chemotherapy, a phase II...
Read more »